Effect of diet-ingested pirfenidone on pulmonary function, cardiovasculature and blood gas measurements in rats

Jim K. Mansoor, Andrew T. Chen, Edward S Schelegle, Shri Giri

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Pirfenidone is an antifibrotic drug that we have shown attenuates the increase in collagen buildup in hamsters exposed to bleomycin, in turn reducing pulmonary function and blood gas decrements seen in this model of interstitial pulmonary fibrosis. The systemic effects of pirfenidone ingestion, however, are unknown. We examined the effect of diet-ingested pirfenidone on pulmonary function, systemic and pulmonary cardiovasculature and blood gas measurements, breathing pattern and lung hydroxyproline content in rats fed either a control diet or a diet containing 0.5% pirfenidone. Residual volume was higher and expiratory reserve volume lower in the pirfenidone group, with no change in functional residual capacity. Tidal volume was also lower in the pirfenidone group, with no change in the overall level of ventilation. There was a trend toward a reduced hydroxyproline content and an increased lung compliance in the pirfenidone group. There were no differences in systemic or pulmonary pressures, cardiac output, stroke volume, heart rate, pH or blood gases between the two groups. These data indicate that pirfenidone has few systemic side-effects but may have a mild effect on the basal level of lung collagen content with resulting clinical changes in some pulmonary function measurements and changes in breathing pattern.

Original languageEnglish (US)
Pages (from-to)260-268
Number of pages9
JournalResearch Communications in Molecular Pathology and Pharmacology
Volume103
Issue number3
StatePublished - Mar 1999

Fingerprint

Gases
Diet
Lung
Hydroxyproline
Expiratory Reserve Volume
Respiration
Collagen
Lung Compliance
Functional Residual Capacity
Residual Volume
pirfenidone
Pulmonary Fibrosis
Tidal Volume
Cricetinae
Cardiac Output
Stroke Volume
Ventilation
Eating
Heart Rate
Pressure

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pathology and Forensic Medicine

Cite this

Effect of diet-ingested pirfenidone on pulmonary function, cardiovasculature and blood gas measurements in rats. / Mansoor, Jim K.; Chen, Andrew T.; Schelegle, Edward S; Giri, Shri.

In: Research Communications in Molecular Pathology and Pharmacology, Vol. 103, No. 3, 03.1999, p. 260-268.

Research output: Contribution to journalArticle

@article{5bc664aab93c4d5dbbb982ea7058183c,
title = "Effect of diet-ingested pirfenidone on pulmonary function, cardiovasculature and blood gas measurements in rats",
abstract = "Pirfenidone is an antifibrotic drug that we have shown attenuates the increase in collagen buildup in hamsters exposed to bleomycin, in turn reducing pulmonary function and blood gas decrements seen in this model of interstitial pulmonary fibrosis. The systemic effects of pirfenidone ingestion, however, are unknown. We examined the effect of diet-ingested pirfenidone on pulmonary function, systemic and pulmonary cardiovasculature and blood gas measurements, breathing pattern and lung hydroxyproline content in rats fed either a control diet or a diet containing 0.5{\%} pirfenidone. Residual volume was higher and expiratory reserve volume lower in the pirfenidone group, with no change in functional residual capacity. Tidal volume was also lower in the pirfenidone group, with no change in the overall level of ventilation. There was a trend toward a reduced hydroxyproline content and an increased lung compliance in the pirfenidone group. There were no differences in systemic or pulmonary pressures, cardiac output, stroke volume, heart rate, pH or blood gases between the two groups. These data indicate that pirfenidone has few systemic side-effects but may have a mild effect on the basal level of lung collagen content with resulting clinical changes in some pulmonary function measurements and changes in breathing pattern.",
author = "Mansoor, {Jim K.} and Chen, {Andrew T.} and Schelegle, {Edward S} and Shri Giri",
year = "1999",
month = "3",
language = "English (US)",
volume = "103",
pages = "260--268",
journal = "Research Communications in Molecular Pathology and Pharmacology",
issn = "1078-0297",
publisher = "PJD Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Effect of diet-ingested pirfenidone on pulmonary function, cardiovasculature and blood gas measurements in rats

AU - Mansoor, Jim K.

AU - Chen, Andrew T.

AU - Schelegle, Edward S

AU - Giri, Shri

PY - 1999/3

Y1 - 1999/3

N2 - Pirfenidone is an antifibrotic drug that we have shown attenuates the increase in collagen buildup in hamsters exposed to bleomycin, in turn reducing pulmonary function and blood gas decrements seen in this model of interstitial pulmonary fibrosis. The systemic effects of pirfenidone ingestion, however, are unknown. We examined the effect of diet-ingested pirfenidone on pulmonary function, systemic and pulmonary cardiovasculature and blood gas measurements, breathing pattern and lung hydroxyproline content in rats fed either a control diet or a diet containing 0.5% pirfenidone. Residual volume was higher and expiratory reserve volume lower in the pirfenidone group, with no change in functional residual capacity. Tidal volume was also lower in the pirfenidone group, with no change in the overall level of ventilation. There was a trend toward a reduced hydroxyproline content and an increased lung compliance in the pirfenidone group. There were no differences in systemic or pulmonary pressures, cardiac output, stroke volume, heart rate, pH or blood gases between the two groups. These data indicate that pirfenidone has few systemic side-effects but may have a mild effect on the basal level of lung collagen content with resulting clinical changes in some pulmonary function measurements and changes in breathing pattern.

AB - Pirfenidone is an antifibrotic drug that we have shown attenuates the increase in collagen buildup in hamsters exposed to bleomycin, in turn reducing pulmonary function and blood gas decrements seen in this model of interstitial pulmonary fibrosis. The systemic effects of pirfenidone ingestion, however, are unknown. We examined the effect of diet-ingested pirfenidone on pulmonary function, systemic and pulmonary cardiovasculature and blood gas measurements, breathing pattern and lung hydroxyproline content in rats fed either a control diet or a diet containing 0.5% pirfenidone. Residual volume was higher and expiratory reserve volume lower in the pirfenidone group, with no change in functional residual capacity. Tidal volume was also lower in the pirfenidone group, with no change in the overall level of ventilation. There was a trend toward a reduced hydroxyproline content and an increased lung compliance in the pirfenidone group. There were no differences in systemic or pulmonary pressures, cardiac output, stroke volume, heart rate, pH or blood gases between the two groups. These data indicate that pirfenidone has few systemic side-effects but may have a mild effect on the basal level of lung collagen content with resulting clinical changes in some pulmonary function measurements and changes in breathing pattern.

UR - http://www.scopus.com/inward/record.url?scp=0032825324&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032825324&partnerID=8YFLogxK

M3 - Article

C2 - 10509737

AN - SCOPUS:0032825324

VL - 103

SP - 260

EP - 268

JO - Research Communications in Molecular Pathology and Pharmacology

JF - Research Communications in Molecular Pathology and Pharmacology

SN - 1078-0297

IS - 3

ER -